Vera Therapeutics, Inc. Class A Actuals & Estimates (NASDAQ:VERA)
This article provides key financial data and analyst insights for Vera Therapeutics, Inc. (NASDAQ:VERA). It covers the stock's recent performance, analyst price targets (ranging from $35.00 to $110.00), historical highs and lows, market capitalization, upcoming earnings reports, and volatility. The company's last earnings report showed a surprise of -27.22%, and it does not pay dividends.
Vera Therapeutics (VERA) CEO sells 18,500 shares under 10b5-1 plan
Vera Therapeutics (VERA) CEO Marshall Fordyce sold a total of 18,500 shares of Class A Common Stock on June 23, 2026, under a pre-arranged Rule 10b5-1(c) trading plan adopted on January 9, 2026. The sales were executed at weighted-average prices of $38.43 and $37.93 per share. Following these transactions, Fordyce directly holds 198,244 shares and indirectly holds an additional 222,030 shares through a trust and a GRAT.
Vera Therapeutics president and CEO Fordyce Marshall sells $701,769 in stock
Fordyce Marshall, President and CEO of Vera Therapeutics, sold 18,500 shares of company stock for over $700,000, executed under a pre-arranged trading plan. This sale follows a period of strong stock performance for Vera Therapeutics, which recently announced positive regulatory developments for its Phase III ORIGIN 3 study. Analysts have reacted positively to these updates, reiterating strong ratings and price targets for the company.
Vera Therapeutics president and CEO Fordyce Marshall sells $701,769 in stock
Fordyce Marshall, President and CEO of Vera Therapeutics, Inc. (NASDAQ:VERA), sold 18,500 shares of the company's Class A Common Stock for $701,769 on June 23, 2026. This transaction was part of a pre-arranged 10b5-1 trading plan and occurred amidst strong stock performance, with VERA shares returning 69% over the past year. Following the sale, Marshall still holds a significant number of shares directly and indirectly, while analysts have reiterated positive ratings for the company due to regulatory developments for its drug atacicept.
Vera Therapeutics (VERA) Is Up 10.7% After Accelerated FDA Timeline For Atacicept IgAN Filing - Has The Bull Case Changed?
Vera Therapeutics recently announced an accelerated FDA timeline for the ORIGIN 3 eGFR analysis for atacicept in IgA nephropathy, supporting a planned supplemental Biologics License Application in Q4 2026. This development clarifies the regulatory pathway and could fast-track full approval, influencing the company's investment narrative. Despite the positive news, Vera Therapeutics remains loss-making with increasing operating expenses, highlighting continued execution risk and potential future funding needs.
Vera Therapeutics (VERA) Stock After FDA Trial Update Has The Valuation Gap Gone Too Far
Vera Therapeutics (VERA) is seeing investor interest after reaching an agreement with the FDA on an earlier eGFR analysis for its ORIGIN 3 trial. While recent stock performance shows a 7.84% rise over 7 days, it's down over 90 days and year-to-date, contrasting with strong longer-term returns. A discounted cash flow (DCF) model suggests the stock is significantly undervalued at $440.11 per share compared to its current price of $34.24, though its P/B ratio indicates it appears expensive relative to industry averages.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics, Inc. announced inducement grants to ten new employees, as approved by its Compensation Committee on June 2, 2026. These grants include non-qualified stock options for 28,800 shares and restricted stock units for 14,150 shares of Class A common stock, issued under the company's 2024 Inducement Plan. The awards are intended to incentivize new employees and comply with Nasdaq Listing Rule 5635(c)(4), with vesting schedules over four years contingent on continued employment.
Vera Therapeutics grants inducement awards to 10 new employees
Vera Therapeutics granted inducement awards to 10 new employees on June 2, 2026. These awards include non-qualified stock options for 28,800 shares with an exercise price of $31.26 and restricted stock units (RSUs) for 14,150 shares. The awards were approved under Nasdaq Listing Rule 5635(c)(4) and will vest over four years, aligning with employment inducement purposes.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announced inducement awards to ten new employees, as approved by its Compensation Committee. These awards include non-qualified stock options for 28,800 shares and restricted stock units for 14,150 shares of Class A common stock, granted under the company's 2024 Inducement Plan. The grants comply with Nasdaq Listing Rule 5635(c)(4) and are designed to incentivize new hires, with vesting periods typically spanning four years.
Vera Therapeutics Grants Inducement Stock Awards to New Employees
Vera Therapeutics granted stock options for 28,800 shares and restricted stock units (RSUs) for 14,150 shares to ten new employees under its 2024 Inducement Plan. These awards, approved by the Compensation Committee in accordance with Nasdaq rules, aim to attract talent, with stock options priced at $31.26 per share, and both options and RSUs vesting over four years. The company focuses on developing treatments for immunological diseases, with lead candidate atacicept.
Vera Therapeutics gives new hires 28,800 stock option shares
Vera Therapeutics (Nasdaq: VERA) announced inducement equity awards for ten new employees under its 2024 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The grants comprise 28,800 stock options at an exercise price of $31.26 and 14,150 Restricted Stock Units (RSUs), both vesting over four years. These awards are intended to attract and retain talent by aligning new hires' interests with the company's long-term success.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announced inducement awards to ten new employees, consisting of non-qualified stock options to purchase 28,800 shares and restricted stock units for 14,150 shares of Class A common stock. These grants were made under the company's 2024 Inducement Plan, consistent with Nasdaq Listing Rule 5635(c)(4), and are subject to multi-year vesting schedules. Vera Therapeutics is a biotechnology company focused on developing treatments for serious immunological diseases, including IgA nephropathy and lupus nephritis, with lead product candidate atacicept.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics reported the granting of inducement awards to ten new employees under its 2024 Inducement Plan, as approved by its Compensation Committee. These awards include non-qualified stock options for 28,800 shares and restricted stock units for 14,150 shares of Class A common stock, intended to incentivize new hires in compliance with Nasdaq Listing Rule 5635(c)(4). The stock options and RSUs have specific vesting schedules over four years, contingent on continued employment with the company.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics, Inc. announced that its Compensation Committee granted inducement awards to ten new employees. These awards, consisting of non-qualified stock options and restricted stock units, were issued on June 2, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4) as a material inducement for their employment. The grants involve 28,800 shares of Class A common stock through stock options and RSUs underlying 14,150 shares, with specific vesting schedules over four years.
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
Vera Therapeutics announced alignment with the U.S. FDA for an earlier ORIGIN Phase 3 eGFR analysis for its drug atacicept, aiming for full approval in adults with IgA Nephropathy (IgAN). This revised schedule could lead to an sBLA submission in Q4 2026 and potential full approval in 2027, accelerating the path for what could be the first approved therapy targeting both BAFF and APRIL for IgAN. The decision is supported by positive eGFR results from the Phase 2b trial and recent discussions with the FDA.
Vera Therapeutics grants 17,084-share option to director | VERA Insider Trading
Vera Therapeutics (VERA) has granted a stock option for 17,084 shares of Class A Common Stock to director James R. Meyers. The options have an exercise price of $34.35 per share and will expire on May 20, 2036. Vesting is contingent on continuous service, occurring on the earlier of one year from the May 21, 2026 grant date or the company's 2027 annual stockholder meeting, with full vesting also triggered by a change in control.
Director at Vera Therapeutics (VERA) receives grant of 17,084 options
Vera Therapeutics director Christy J. Oliger received a grant of 17,084 stock options at an exercise price of $34.35 per share, awarded as compensation. These options will fully vest on the earlier of the first anniversary of the grant date or the company's 2027 annual shareholder meeting, contingent on Oliger's continuous service. The options, which expire on May 20, 2036, also fully vest upon a change of control if she remains in service.
Vera Therapeutics (VERA) awards director 17,084 stock options
Vera Therapeutics director Michael Morrissey was granted 17,084 stock options for Class A Common Stock. These options have an exercise price of $34.35 and expire in 2036. They vest fully on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, contingent on continuous service, and also vest fully upon a change in control.
Vera Therapeutics (VERA) director Beth Seidenberg receives 17,084-share stock option grant
Vera Therapeutics director Beth C. Seidenberg was granted stock options for 17,084 Class A common shares with an exercise price of $34.35 per share. These options are part of a compensation package and will vest fully on the earlier of the first anniversary of the grant date or the company's 2027 annual stockholder meeting, provided continuous service. Full vesting also occurs upon a change in control if she remains in service.
[8-K] Vera Therapeutics, Inc. Reports Material Event
Vera Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders. Shareholders elected three Class II directors, ratified KPMG LLP as the independent registered public accounting firm, and approved executive compensation in an advisory vote. The company detailed the voting results for each proposal.
Director at Vera Therapeutics (VERA) receives 17,084 stock options with $34.35 strike
Vera Therapeutics director Scott W. Morrison was granted 17,084 stock options with an exercise price of $34.35 per share. These options vest upon the earlier of the first anniversary of the grant date, the 2027 annual stockholder meeting, or a change in control, contingent on his continued service. Following this grant, Morrison directly holds options for 17,084 shares.
Vera Therapeutics (VERA) director awarded options on 17,084 shares
Vera Therapeutics director Kimball Hall was granted stock options for 17,084 shares of Class A common stock at an exercise price of $34.35 per share. These options are set to expire on May 20, 2036, and will vest fully on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, provided Hall maintains continuous service. Full vesting will also occur upon a change in control, subject to continuous service.
Director Patrick Enright awarded 17,084 Vera Therapeutics (VERA) stock options
Vera Therapeutics director Patrick G. Enright was granted 17,084 stock options for Class A common stock with an exercise price of $34.35 per share. The options expire on May 20, 2036, and will vest fully on the earlier of the first anniversary of the grant date or the company's 2027 annual stockholder meeting, subject to continuous service. Full vesting is also triggered upon a change in control if Enright's service continues.
Vera Therapeutics (VERA) Is Down 11.6% After Wider Q1 Loss Highlights Rising Cost Burden
Vera Therapeutics (VERA) reported a significantly wider net loss of US$121.03 million in Q1 2026, compared to US$51.69 million a year prior, leading to an 11.6% stock price drop. This increased loss is primarily due to rising costs and investments, particularly ahead of the July 2026 PDUFA decision for atacicept. The market is pricing in higher execution and financing risk, with analysts' fair value estimates varying widely, underscoring the uncertainty surrounding the company’s future.
Vera Therapeutics president and CEO sells $679,747 in stock
Vera Therapeutics President and CEO, Fordyce Marshall, sold approximately $679,747 worth of the company's Class A Common Stock on May 12, 2026, through two separate transactions under a Rule 10b5-1 trading plan. Despite the insider sale and a 23% year-to-date decline, the stock has shown an 81% return over the past year and is considered undervalued by InvestingPro. The company has also recently received positive analyst ratings and appointed a new board member.
Vera Therapeutics, Inc. - Class A Common Stock (NQ: VERA)
This page provides news headlines related to Vera Therapeutics, Inc. (Nasdaq: VERA), along with stock information and market updates. The articles cover various financial news, including analyst ratings, IPOs, and biotech sector movements from May and June 2021. One key highlight is Vera Therapeutics' IPO pricing below its target range in May 2021.
T. Rowe Price (VERA) reports 4.57M shares, 6.4% ownership (Amendment)
T. Rowe Price Associates, Inc. has filed an Amendment No. 3 to Schedule 13G/A, disclosing beneficial ownership of 4,573,684 shares of Vera Therapeutics Inc. common stock, which represents 6.4% of the class. The filing specifies sole voting power over 4,570,810 shares and sole dispositive power over 4,573,684 shares. Notably, T. Rowe Price explicitly denies beneficial ownership in the filing, stating it should not be construed as an admission.
Vera Therapeutics, Inc. - Class A Common Stock (NQ: VERA)
This page provides a collection of recent news headlines related to Vera Therapeutics, Inc. (Nasdaq: VERA), primarily from Benzinga and The Motley Fool. The articles cover analyst forecasts, quarterly earnings recaps, stock movements, and updates on clinical trials and insider trading. The content highlights significant stock performance events and regulatory updates for the company.
Vera Therapeutics president and CEO sells $679,747 in stock
Fordyce Marshall, President and CEO of Vera Therapeutics, Inc. (NASDAQ:VERA), sold approximately $679,747 worth of Class A Common Stock on May 12, 2026, under a Rule 10b5-1 trading plan. The sales involved 18,500 shares across two transactions at weighted-average prices around $36.63 and $37.08. Despite a 23% year-to-date decline, VERA shares have seen an 81% return over the past year, while the company maintains a strong financial position with more cash than debt.
Vera Therapeutics president and CEO sells $679,747 in stock By Investing.com
Vera Therapeutics President and CEO, Fordyce Marshall, sold approximately $679,747 worth of Class A Common Stock on May 12, 2026, across two separate transactions. Despite an 81% return for VERA shares over the past year, the stock has declined 23% year-to-date and is considered undervalued by InvestingPro. Marshall still retains a significant number of shares, both directly and indirectly, and the company has recently received positive analyst upgrades and appointed a new board member.
Vera Therapeutics (VERA) CEO sells 18,500 shares under 10b5-1 plan
Vera Therapeutics (VERA) President and CEO Marshall Fordyce sold a total of 18,500 shares of Class A common stock on May 12, 2026. The sales were executed under a pre-established Rule 10b5-1 trading plan adopted on January 9, 2026, with the shares sold in two tranches at weighted-average prices of $37.0868 and $36.6396. Following these transactions, Fordyce's indirect holdings through a trust and a GRAT still exceed 200,000 shares.
A Look At Vera Therapeutics (VERA) Valuation After FDA Priority Review For Atacicept In IgA Nephropathy
Vera Therapeutics (VERA) is facing a critical period with its drug atacicept awaiting FDA review for IgA nephropathy, despite reporting a significant net loss in the first quarter. While the stock has seen recent declines, its long-term shareholder return remains strong, and analysts anticipate high revenue and earnings growth. The company's valuation appears high based on its P/B ratio compared to industry averages, but a Discounted Cash Flow model suggests a substantial undervaluation relative to future cash flow estimates.
Does Vera’s Widening Quarterly Net Loss Reframe the Bull Case for Vera Therapeutics (VERA)?
Vera Therapeutics (VERA) reported a significant increase in its Q1 2026 net loss, reaching US$121.03 million, more than double the previous year, primarily due to heavy upfront spending on atacicept development. This widening loss intensifies questions about cash burn, future financing, and potential equity dilution. Despite this, the investment narrative still centers on atacicept's IgA nephropathy opportunity and the upcoming FDA PDUFA date of July 7, 2026.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics, Inc. announced inducement awards for ten new employees, granted on May 4, 2026, under its 2024 Inducement Plan. These awards include non-qualified stock options to purchase 40,250 shares and restricted stock units (RSUs) underlying 20,125 shares, approved in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options and RSUs will vest over four years, contingent on continued employment.
Ten new hires get Vera stock awards tied to 60,375 shares
Vera Therapeutics (Nasdaq: VERA) announced inducement awards on May 4, 2026, granting non-qualified stock options for 40,250 shares and Restricted Stock Units (RSUs) for 20,125 shares to ten new employees under its 2024 Inducement Plan. The stock options have an exercise price of $35.51, matching the closing price on the grant date, and both options and RSUs will vest over four years, subject to continued employment. This move follows similar grants and aims to attract and retain talent in line with Nasdaq Listing Rule 5635(c)(4).
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics has announced inducement awards for ten new employees, consisting of non-qualified stock options to purchase 40,250 shares and restricted stock units (RSUs) underlying 20,125 shares of Class A common stock. These grants were made on May 4, 2026, under the company's 2024 Inducement Plan, with an exercise price of $35.51 per stock option. The awards are structured with vesting schedules over four years, contingent on continued employment.
B-K] Vera Therapeutics, Inc. Reports Material Event
Vera Therapeutics, Inc. reported its first-quarter 2026 financial results and provided business updates, highlighting the FDA's Priority Review for atacicept for IgA nephropathy with a PDUFA date of July 7, 2026. The company posted a net loss of $121.0 million, an increase from the previous year, as it ramped up R&D and commercial launch preparations. Vera Therapeutics confirmed it has sufficient cash reserves and debt facilities to fund operations through the potential approval and U.S. commercial launch of atacicept.
Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference
Vera Therapeutics, Inc. announced its management team will present at the Bank of America Securities 2026 Health Care Conference in Las Vegas from May 12-14, 2026. The company, focused on developing treatments for serious immunological diseases, will also hold one-on-one investor meetings. A webcast of the presentation on May 13, 2026, at 4:20 PM PDT will be available, with a replay accessible on their website.
Fordyce, Vera Therapeutics CEO, sells $1m in VERA stock By Investing.com
Marshall Fordyce, President and CEO of Vera Therapeutics, Inc. (NASDAQ:VERA), sold 22,951 shares of Class A Common Stock for over $1 million on April 14, 2026. These sales, executed under a pre-arranged trading plan, occurred as VERA stock saw significant gains, with the company currently valued at $3.1 billion and its next earnings report due on May 7. The article also notes recent positive analyst ratings and strategic appointments within Vera Therapeutics.
Fordyce, Vera Therapeutics CEO, sells $1m in VERA stock
Marshall Fordyce, President and CEO of Vera Therapeutics, Inc., sold 22,951 shares of Class A Common Stock for over $1 million on April 14, 2026, through a pre-arranged trading plan. This sale occurred while VERA stock has shown significant gains, and analyst ratings remain positive, with the company valued at $3.1 billion ahead of its next earnings report.
[Form 4] Vera Therapeutics, Inc. Insider Trading Activity
Vera Therapeutics, Inc.'s President and CEO, Marshall Fordyce, reported open-market sales of Class A Common Stock on April 14, 2026. These transactions, executed under a pre-arranged Rule 10b5-1(c) trading plan, involved the sale of 22,951 shares totaling approximately $1.01 million. Following these sales, Fordyce retains significant direct and indirect holdings in the company.
Fordyce, Vera Therapeutics CEO, sells $1m in VERA stock
Marshall Fordyce, President and CEO of Vera Therapeutics, Inc. (NASDAQ:VERA), sold 22,951 shares of Class A Common Stock worth over $1 million on April 14, 2026, under a pre-arranged 10b5-1 trading plan. Despite the insider sale, VERA stock has performed strongly, gaining 10% in the past week and 105% in the past year, and analysts have recently reiterated Buy and Overweight ratings with positive price targets. The company, valued at $3.1 billion, is preparing for its next earnings report on May 7 and has made strategic appointments to its board and commercial team.
Vera Therapeutics (VERA) Valuation Check After Recent Share Price Rebound
Vera Therapeutics (VERA) has seen a recent share price rebound, up 10% in the past day and week, though year-to-date it's down 7.36%. The stock trades at a Price-to-Book ratio of 5.3x, which is above the US biotech industry average but below its direct peers, suggesting it's about right. However, a discounted cash flow (DCF) model from Simply Wall St indicates the stock is heavily undervalued, trading at US$45.04 against a calculated intrinsic value of US$436.34 per share, creating conflicting valuation signals for investors.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics, Inc. announced inducement awards to 89 new employees, consisting of non-qualified stock options to purchase 258,200 shares and restricted stock units (RSUs) for 131,925 shares of Class A common stock. These grants were made under the company's 2024 Inducement Plan and approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options and RSU awards will vest over four years, subject to continued employment.
Vera Therapeutics issues stock awards to 89 new employees
Vera Therapeutics announced it granted inducement awards to 89 new employees on April 8, 2026, under its 2024 Inducement Plan. These awards include non-qualified stock options for 258,200 shares and restricted stock units (RSUs) for 131,925 shares. The stock options have an exercise price of $40.33 and both options and RSUs vest over four years, aligning with Vera Therapeutics' strategy of using equity for hiring and retention.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announced inducement awards to 89 new employees, consisting of non-qualified stock options and restricted stock units (RSUs), under its 2024 Inducement Plan. These grants, made on April 8, 2026, were approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4) and are designed to incentivize new hires. The awards have specific vesting schedules tied to continued employment with the company.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics announced it granted inducement awards to 89 new employees, consisting of non-qualified stock options to purchase 258,200 shares and restricted stock units (RSUs) for 131,925 shares of Class A common stock. These awards, approved by the Compensation Committee, are in accordance with Nasdaq Listing Rule 5635(c)(4) and are designed to attract new talent. Both the stock options and RSUs will vest over a four-year period, subject to continued employment.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics, Inc. announced that its Compensation Committee granted inducement awards on April 8, 2026, to 89 new employees. These awards consist of non-qualified stock options to purchase 258,200 shares and restricted stock units (RSUs) for 131,925 shares of Class A common stock, issued under the company's 2024 Inducement Plan. The grants aim to incentivize new hires, with vesting periods set over four years for both stock options and RSUs.
Board of Vera Therapeutics (VERA) seeks votes on directors, auditor and say-on-pay
Vera Therapeutics (VERA) has scheduled its 2026 Annual Meeting of Stockholders for May 21, 2026, to be held virtually. Stockholders will vote on electing three Class II directors, ratifying KPMG LLP as the independent auditor for 2026, and approving an advisory "say-on-pay" resolution for executive compensation. The board recommends voting in favor of all three proposals.
Is It Too Late To Consider Vera Therapeutics (VERA) After Its Recent Share Price Surge?
Vera Therapeutics (VERA) has seen a significant share price surge, up 102.8% over the past year, prompting questions about its current valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued, estimating an intrinsic value of $436.72 per share against a recent price of $40.45. While its Price-to-Book (P/B) ratio of 4.77x is higher than the industry average, the overall assessment suggests the stock could still offer value, especially considering future cash flow projections.
